iPS Cell-Derived Organ Bud Formation via Synchronized Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for constructing three-dimensional organs from pluripotent stem cells face challenges such as variability in organ primordia quality due to donor dependence, limited growth capacity, immunocompatibility issues, and difficulty in achieving terminal differentiation and vascularization, leading to immature tissue function.
Innovation Solution
The method involves synchronizing the differentiation of multiple cell species from induced pluripotent stem cells (iPS cells) to recapitulate early organogenesis processes, using iPS cell-derived hepatic endoderm, vascular endothelial, and mesenchymal cells, and transplanting these cells to induce vascularization and terminal differentiation, forming functional three-dimensional organ buds with vascular networks.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods use umbilical cord-derived vascular endothelial cells and bone marrow-derived mesenchymal cells, then organ primordia can be formed, but quality varies greatly depending on donors and immunocompatibility is difficult to secure
Solution Approach 1:
The patent uses iPS cells as a common source for all three cell types (hepatic endoderm, vascular endothelial, and mesenchymal cells), ensuring homogeneous genetic background and eliminating donor variability. This homogenization strategy resolves the contradiction by providing consistent quality while maintaining the ability to generate multiple cell types from a single pluripotent source.
Solution Approach 2:
The patent employs iPS cells with multi-functional capacity to differentiate into all required cell types (hepatic endoderm, vascular endothelial, and mesenchymal cells). This universal cell source eliminates the need for multiple donor sources, thereby ensuring quality stability while maintaining versatility in generating diverse cell populations for organ primordia construction.
2Productivity
If umbilical cord/bone marrow-derived cells are used, then organ primordia can be prepared, but growth capacities of cell sources are limited
Solution Approach 1:
The patent performs preliminary expansion of iPS cells before differentiating them into specific cell types. This preliminary action allows sufficient accumulation of cell numbers and genetic material, enabling large-scale production of organ primordia without being constrained by the limited growth capacity of matured cells from umbilical cord or bone marrow sources.
Solution Approach 2:
The patent utilizes the undifferentiated state of iPS cells, which have superior proliferation capacity compared to matured cells. By maintaining cells in a pluripotent or progenitor state and controlling differentiation timing, the system achieves both high productivity and sustained growth capacity, resolving the contradiction between production volume and cell source limitations.
3Manufacturing precision
If matured cells from umbilical cord and bone marrow are used, then organ primordia can be formed, but cells greatly differ in differentiation stage from immature cells required for organogenesis
Solution Approach 1:
The patent performs preliminary differentiation of iPS cells into specific progenitor populations (hepatic endoderm, vascular endothelial, and mesenchymal cells) before combining them to form organ primordia. This preliminary action ensures all cell types are at appropriate immature stages matching in vivo organogenesis requirements, achieving precise differentiation stage synchronization while simplifying the overall cell source strategy through a single iPS cell origin.
4Manufacturing precision
If conventional directed differentiation methods are used with various differentiation factors, then cell differentiation can be induced, but terminally differentiated functional cells cannot be achieved
Solution Approach 1:
The patent employs a two-stage differentiation strategy where iPS cells are first differentiated into specific progenitor populations, which are then combined in three-dimensional culture to undergo spontaneous terminal differentiation. This preliminary action into progenitor states, followed by in situ maturation in the organ primordia structure, achieves terminal differentiation of functional cells more effectively than conventional direct differentiation methods.
Solution Approach 2:
The patent allows the combined progenitor cells to undergo spontaneous terminal differentiation and self-organization within the three-dimensional organ primordia structure. This self-service approach, where cells automatically differentiate and mature when placed in the appropriate three-dimensional context with neighboring cell types, achieves terminal differentiation without requiring complex external differentiation factor regimens.
5Reliability
If scaffold-based methods are used to reconstitute human tissues and organs, then tissue structure can be formed, but seeded functional cells have extremely low engraft rate and long-term culture is difficult
Solution Approach 1:
The patent extracts and eliminates the scaffold component from conventional tissue reconstitution methods. By using only cell-cell interactions and spontaneous self-organization of progenitor cells in three-dimensional suspension culture, the system achieves high engraft rates and long-term culture capability without the complexity and limitations of scaffold materials.
Solution Approach 2:
The patent enables progenitor cells to spontaneously self-organize into three-dimensional organ primordia structures with proper tissue architecture and vascular networks through cell-cell interactions alone. This self-service capability, where cells automatically form functional structures without external scaffolding, achieves high engraft rates and sustained long-term culture while eliminating scaffold-related complexities.
Data Source
AI summary
The present disclosure relates to an organ bud and a method of preparing an organ bud.